Arbutus Biopharma’s (ABUS) Hold Rating Reiterated at Echelon Wealth Partners

Share on StockTwits

Arbutus Biopharma (NASDAQ:ABUS)‘s stock had its “hold” rating reaffirmed by equities researchers at Echelon Wealth Partners in a research report issued to clients and investors on Monday.

Several other research analysts also recently commented on ABUS. Zacks Investment Research raised Arbutus Biopharma from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Tuesday, February 12th. BidaskClub raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a report on Tuesday, March 5th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $6.50 target price on shares of Arbutus Biopharma in a report on Sunday, March 10th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $6.25.

Shares of ABUS opened at $3.75 on Monday. The stock has a market cap of $223.36 million, a price-to-earnings ratio of -3.68 and a beta of 1.81. Arbutus Biopharma has a 12 month low of $3.20 and a 12 month high of $12.60.

Arbutus Biopharma (NASDAQ:ABUS) last announced its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.02. The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.77 million. Arbutus Biopharma had a negative return on equity of 74.52% and a negative net margin of 986.23%. Equities analysts anticipate that Arbutus Biopharma will post -1.31 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc lifted its holdings in Arbutus Biopharma by 15.8% during the 4th quarter. Legal & General Group Plc now owns 28,407 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 3,867 shares during the period. Teachers Advisors LLC raised its position in shares of Arbutus Biopharma by 12.5% in the 3rd quarter. Teachers Advisors LLC now owns 75,945 shares of the biopharmaceutical company’s stock worth $718,000 after acquiring an additional 8,428 shares in the last quarter. Rhumbline Advisers raised its position in shares of Arbutus Biopharma by 45.9% in the 4th quarter. Rhumbline Advisers now owns 49,032 shares of the biopharmaceutical company’s stock worth $188,000 after acquiring an additional 15,416 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Arbutus Biopharma by 46.9% in the 3rd quarter. Wells Fargo & Company MN now owns 68,063 shares of the biopharmaceutical company’s stock worth $644,000 after acquiring an additional 21,737 shares in the last quarter. Finally, Foresite Capital Management IV LLC raised its position in shares of Arbutus Biopharma by 0.9% in the 3rd quarter. Foresite Capital Management IV LLC now owns 2,676,825 shares of the biopharmaceutical company’s stock worth $25,296,000 after acquiring an additional 25,000 shares in the last quarter. 42.92% of the stock is currently owned by hedge funds and other institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company, engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.

Featured Story: Debt-To-Equity Ratio

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Edap Tms  Given a $7.00 Price Target at HC Wainwright
Edap Tms Given a $7.00 Price Target at HC Wainwright
Dynex Capital  Upgraded by Zacks Investment Research to “Hold”
Dynex Capital Upgraded by Zacks Investment Research to “Hold”
Carter’s, Inc.  Shares Sold by American International Group Inc.
Carter’s, Inc. Shares Sold by American International Group Inc.
American Money Management LLC Has $3.98 Million Stake in Paychex, Inc.
American Money Management LLC Has $3.98 Million Stake in Paychex, Inc.
Marathon Petroleum Corp  Shares Sold by American Financial Network Advisory Services LLC
Marathon Petroleum Corp Shares Sold by American Financial Network Advisory Services LLC
Alpha Quant Advisors LLC Purchases New Holdings in Quest Diagnostics Inc
Alpha Quant Advisors LLC Purchases New Holdings in Quest Diagnostics Inc


© 2006-2019 Ticker Report